Abstract: . . .  oral cefixime therapy for treatment of bacterial conjunctivitis . Pediatr Infect Dis J 2001;20:10391042. 38. Stern GA, Killingsworth DW. Complications of topical antimicrobial agents. Int Ophthalmol Clin 1989;29:137142. 39. Schwab IR, Friedlaender M, McCulley J, et al, and the Levofloxacin Bacterial Conjunctivitis Active Control Study Group. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis . Ophthalmology 2003;110:457465. Justine Smith Assistant Professor of Ophthalmology Casey Eye Institute Oregon Health & Science University Portland USA Competing interests: None declared. Bacterial conjunctivitis Eye disorders 840 BMJ Publishing Group Ltd 2004 </html . . .
. . .  bacterial conjunctivitis : 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Can J Ophthalmol 2002;37:228237. 36. Sinclair, Leigh DA. A comparison of fusidic acid viscous eye drops and chloramphenicol eye ointment in acute conjunctivitis . Curr Ther Res 1988;44:468474. 37. Wald ER, Greenberg D, Hoberman A. Short term oral cefixime therapy for treatment of bacterial conjunctivitis . Pediatr Infect Dis J 2001;20:10391042. 38. Stern GA, Killingsworth DW. Complications of topical antimicrobial agents. Int Ophthalmol Clin 1989;29:137142. 39. Schwab IR, Friedlaender M, McCulley J, et al, and the Levofloxacin Bacterial Conjunctivitis Active Control Study Group. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis . Ophthalmology 2003;110:457465. Justine Smith Assistant Professor of Ophthalmology Casey Eye Institute Oregon Health & Science University Portland USA Competing interests: None declared. Bacterial conjunctivitis Eye disorders 840 BMJ Publishing Group Ltd 2004 </html . . .
--3000,2,750,2411,25334